retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial Mounjaro: and Diabetes Eli Lilly's retatrutide shows promising
Description
There are many obesity-related complications, including type 2 diabetes, heart disease, obstructive sleep apnea, chronic kidney disease, non-alcoholic fatty liver disease, and cancer
March 3, 2025: Go-Forward Plan in Ozempic Lawsuits Discussed During Status Hearing In a recent status conference for the Ozempic group lawsuit, Judge Karen Spencer Marston discussed a number of important milestones for GLP-1 lawsuits in 2025
In a landmark development, liraglutide (Saxenda) was approved in 2020 for use in adolescents aged 12-17 years with a body weight above 60 kg and an initial BMI corresponding to 30 kg/m for adults [17]
Clinical Development Pipeline
doi: 10.1007/s00125-017-4330-3
(For example SPs Whole Food Fiber product supports bowel function and beneficial microorganisms)
